Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand.
Drugs. 2013 Jul;73(11):1227-44. doi: 10.1007/s40265-013-0088-1.
The live, attenuated shingles (herpes zoster) vaccine Zostavax(®) is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. In adults aged ≥60 years, zoster vaccine reduced the burden of illness associated with herpes zoster, with reductions in the incidence of postherpetic neuralgia and herpes zoster, according to the results of the Shingles Prevention Study. Results of subsequent Short- and Long-Term Persistence Substudies indicate that the efficacy of zoster vaccine is maintained in the longer term, albeit with a gradual decline over time. In the Zostavax Efficacy and Safety Trial, zoster vaccine reduced the incidence of herpes zoster in adults aged 50-59 years. Findings of these studies are supported by the results of large, retrospective, cohort studies. Zoster vaccine was generally well tolerated, with injection-site adverse events being the most commonly reported adverse events. In conclusion, zoster vaccine provides an important opportunity to reduce the burden of illness associated with herpes zoster by reducing the incidence of herpes zoster and postherpetic neuralgia.
活疫苗（带状疱疹）Zostavax(®)已在欧盟获得批准，用于预防 50 岁及以上成人的带状疱疹和带状疱疹后神经痛。在 60 岁及以上成人中，带状疱疹疫苗可降低与带状疱疹相关的疾病负担，根据带状疱疹预防研究的结果，带状疱疹后神经痛和带状疱疹的发病率均有所降低。随后的短期和长期持续亚研究的结果表明，带状疱疹疫苗的疗效在长期内保持，但随着时间的推移逐渐下降。在 Zostavax 疗效和安全性试验中，带状疱疹疫苗降低了 50-59 岁成人的带状疱疹发病率。这些研究的结果得到了大型回顾性队列研究结果的支持。带状疱疹疫苗总体上具有良好的耐受性，最常见的不良反应为注射部位不良反应。总之，带状疱疹疫苗通过降低带状疱疹和带状疱疹后神经痛的发病率，为降低与带状疱疹相关的疾病负担提供了一个重要机会。
